BioCryst Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.0000
- Today's High:
- $13.1500
- Open Price:
- $12.5000
- 52W Low:
- $7.61
- 52W High:
- $19.99
- Prev. Close:
- $11.8600
- Volume:
- 5043626
Company Statistics
- Market Cap.:
- $2.235 billion
- Book Value:
- 0.191
- Revenue TTM:
- $0.204 billion
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-0.059 billion
- Gross Profit TTM:
- $-0.059 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- -28.8%
- Return on Equity TTM:
- -1925%
Company Profile
BioCryst Pharmaceuticals Inc had its IPO on 1994-03-04 under the ticker symbol BCRX.
The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. BioCryst Pharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of BioCryst Pharmaceuticals Inc opened at $12.5 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $12 - $13.15, and closed at $12.02.
This is a +1.35% increase from the previous day's closing price.
A total volume of 5,043,626 shares were traded at the close of the day’s session.
In the last one week, shares of BioCryst Pharmaceuticals Inc have slipped by -14.14%.
BioCryst Pharmaceuticals Inc's Key Ratios
BioCryst Pharmaceuticals Inc has a market cap of $2.235 billion, indicating a price to book ratio of 56.59 and a price to sales ratio of 12.61.
In the last 12-months BioCryst Pharmaceuticals Inc’s revenue was $0.204 billion with a gross profit of $-0.059 billion and an EBITDA of $-0.180 billion. The EBITDA ratio measures BioCryst Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BioCryst Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -28.8% with a return of equity of -1925%.
In Q2, BioCryst Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 31.2%.
BioCryst Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- -0.28
Its diluted EPS in the last 12-months stands at $-1.072 per share while it has a forward price to earnings multiple of - and a PEG multiple of -0.28. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioCryst Pharmaceuticals Inc’s profitability.
BioCryst Pharmaceuticals Inc stock is trading at a EV to sales ratio of 11.52 and a EV to EBITDA ratio of -18.85. Its price to sales ratio in the trailing 12-months stood at 12.61.
BioCryst Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
BioCryst Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
BioCryst Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
BioCryst Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, BioCryst Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, BioCryst Pharmaceuticals Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $12.02
- 52-Week High
- $19.99
- 52-Week Low
- $7.61
- Analyst Target Price
- $17.6
BioCryst Pharmaceuticals Inc stock is currently trading at $12.02 per share. It touched a 52-week high of $19.99 and a 52-week low of $19.99. Analysts tracking the stock have a 12-month average target price of $17.6.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About BioCryst Pharmaceuticals Inc
Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))
Most Active
Top Gainers
Top Losers
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.